Background:The Plasmodium vivax Apical Membrane Antigen 1 (PvAMA1) is a promising malaria vaccine candidate, however it remains unclear which regions are naturally targeted by host immunity and whether its high genetic diversity will preclude coverage by a monovalent vaccine. To assess its feasibility as a vaccine candidate, we investigated the global population structure of PvAMA1.Methodology and Principal Findings:New sequences from Papua New Guinea (PNG, n = 102) were analysed together with published sequences from Thailand (n = 158), India (n = 8), Sri Lanka (n = 23), Venezuela (n = 74) and a collection of isolates from disparate geographic locations (n = 8). A total of 92 single nucleotide polymorphisms (SNPs) were identified including...
Although Plasmodium vivax is a leading cause of malaria around the world, only a handful of vivax an...
<div><p>Infection with <i>Plasmodium knowlesi</i>, a zoonotic primate malaria, is a growing human he...
After more than 50 years of intensive research and development, only one malaria vaccine candidate, ...
BACKGROUND: The Plasmodium vivax Apical Membrane Antigen 1 (PvAMA1) is a promising malaria vaccine c...
Although Plasmodium vivax is a leading cause of malaria around the world, only a handful of vivax an...
Present study describes the characterization of apical membrane antigen 1 (PvAMA1) polymorphisms amo...
BackgroundWith the premise of diminishing parasite genetic diversity following the reduction of mala...
Background: As Plasmodium falciparum and Plasmodium vivax co-exist in most malaria-endemic regions o...
<div><p>Although <i>Plasmodium vivax</i> is a leading cause of malaria around the world, only a hand...
Plasmodium vivax is the most widespread malaria species parasitizing humans outside Africa, with app...
The extensive diversity of Plasmodium falciparum antigens is a major obstacle to a broadly effective...
Plasmodium vivax is the most widespread cause of human malaria. Recent reports of drug resistan...
Block II of Plasmodium vivaxmerozoite surface protein 3α (PvMSP3α) is conserved and has been propose...
Polymorphic regions of the genes encoding Plasmodium vivax apical membrane antigen 1 (PvAMA1) and P....
Block II of Plasmodium vivax merozoite surface protein 3α (PvMSP3α) is conserved and has been propos...
Although Plasmodium vivax is a leading cause of malaria around the world, only a handful of vivax an...
<div><p>Infection with <i>Plasmodium knowlesi</i>, a zoonotic primate malaria, is a growing human he...
After more than 50 years of intensive research and development, only one malaria vaccine candidate, ...
BACKGROUND: The Plasmodium vivax Apical Membrane Antigen 1 (PvAMA1) is a promising malaria vaccine c...
Although Plasmodium vivax is a leading cause of malaria around the world, only a handful of vivax an...
Present study describes the characterization of apical membrane antigen 1 (PvAMA1) polymorphisms amo...
BackgroundWith the premise of diminishing parasite genetic diversity following the reduction of mala...
Background: As Plasmodium falciparum and Plasmodium vivax co-exist in most malaria-endemic regions o...
<div><p>Although <i>Plasmodium vivax</i> is a leading cause of malaria around the world, only a hand...
Plasmodium vivax is the most widespread malaria species parasitizing humans outside Africa, with app...
The extensive diversity of Plasmodium falciparum antigens is a major obstacle to a broadly effective...
Plasmodium vivax is the most widespread cause of human malaria. Recent reports of drug resistan...
Block II of Plasmodium vivaxmerozoite surface protein 3α (PvMSP3α) is conserved and has been propose...
Polymorphic regions of the genes encoding Plasmodium vivax apical membrane antigen 1 (PvAMA1) and P....
Block II of Plasmodium vivax merozoite surface protein 3α (PvMSP3α) is conserved and has been propos...
Although Plasmodium vivax is a leading cause of malaria around the world, only a handful of vivax an...
<div><p>Infection with <i>Plasmodium knowlesi</i>, a zoonotic primate malaria, is a growing human he...
After more than 50 years of intensive research and development, only one malaria vaccine candidate, ...